AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 61 min read$BLFS

BioLife Solutions Received Notice of Delisting

BioLife Solutions (BLFS) ceased trading on Nasdaq on Oct 6, 2026, following its merger with Repligen. The company requested delisting and deregistration of its common stock, and plans to terminate reporting obligations. Trading was halted post-market on Oct 5, 2026.

Original reporting
tradingview.com
Published Oct 6, 2026, 1:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 1:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BioLife Solutions Received Notice of Delisting — source image
Source · tradingview.com
Decision brief

The 30-second read

$BLFSBearishMed
01

Why it matters

The filing triggers an immediate suspension of trading and a likely sell‑off, reducing market depth for BLFS.

02

Market read

Primary corporate action with direct impact on BLFS price and liquidity; limited spillover to broader market.

03

What to watch

Potential for a reverse merger or private placement that could restore liquidity, and any pending clinical data that may offset delisting concerns.

Relevance 6/10Novelty 7/10Timing: post‑market Oct 6, 2026

Background

BioLife Solutions completed a merger with Repligen, after which it no longer met Nasdaq's listing standards.

Company-level read

Ticker impact

$BLFSBearishHigh confidence
Context

BioLife Solutions filed an 8‑K announcing Nasdaq delisting and suspension of its common stock after its merger with Repligen.

Expected impact

likely pressure as the market prices in the delisting and loss of exchange listing

Evidence & confidence

A primary SEC filing (Form 8‑K) discloses a material corporate action; such events typically trigger sell‑offs.

Market effects

Sector

Biotech sector may see slight negative sentiment as a peer loses Nasdaq listing.

Regional

US market impact limited to BLFS shareholders; no broader regional effect.

Global

Minimal global relevance beyond the specific ticker.

Counterpoint

What could challenge this read

If the delisting is temporary and the company can relist on another exchange, the price dip could be a buying opportunity.

Key entities

  • Company
    BioLife Solutions Inc.

    US‑listed biotech company (ticker BLFS) undergoing delisting after merger.

  • Company
    Repligen Corp.

    Merger partner whose combination caused the listing deficiency.

Read at source← All news

Related articles

OCT 6
$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

SEC EDGAR 8-K2 min
OCT 6
$BLFSHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

SEC EDGAR 8-K2 min
OCT 6
$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

globenewswire.com1 min
OCT 5
$FRSHHighAI 8/10

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.

securities.io3 min
SEP 4
$BLFSMedAI 8/10

[DEFM14A] BIOLIFE SOLUTIONS INC Merger Proxy Statement

BioLife Solutions (BLFS) filed a proxy statement for a merger with Repligen. The deal offers $11.25 and 0.1442 Repligen shares per BioLife share, pending stockholder approval on October 5, 2026. BioLife stock will be delisted if the merger completes. Repligen's share count will increase, diluting existing holders.

stocktitan.net2 min